4 days ago · EMBLAVEO TM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria; Gram-negative bacterial infections represent a significant public health threat due to their ability to develop resistance to antimicrobial therapies

EMBLAVEO for complicated intra-abdominal infections in adults caused by designated susceptible gram-negative microorganisms. See full Prescribing Information.

EMBLAVEO safely and effectively. See full prescribing information for EMBLAVEO. c EMBLAVEO (aztreonam and avibactam) for injection, for intravenous use Initial U.S. Approval: 2025 INDICATIONS AND USAGE EMBLAVEO is a combination of aztreonam, a monobactam antibacterial, and avibactam, a beta-lactamase inhibitor, that when used in

20 hours ago · Emblaveo is supplied in a single-dose vial as a lyophilized powder containing 1.5g of aztreonam and 0.5g of avibactam that requires reconstitution and dilution prior to IV infusion. The ...

4 days ago · EMBLAVEO is a medication that combines two components: aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor that protects aztreonam from serine β-lactamase hydrolysis and ...

Apr 22, 2024 · EMBLAVEO ® is the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating serious infections in adult patients caused by multidrug-resistant Gram-negative bacteria, including metallo-β-lactamase-producing bacteria

Mar 22, 2024 · Emblaveo is an antibiotic used in adults to treat: Complicated (difficult to treat) intra-abdominal (belly) infections; Hospital-acquired pneumonia (an infection of the lungs that is caught during a hospital stay), including ventilator-associated pneumonia (pneumonia that develops in patients who use a machine called a ventilator to help them ...

What is Emblaveo and what is it used for? Emblaveo is an antibiotic medicine that contains two active substances aztreonam and avibactam. Aztreonam belongs to the group of antibiotics called “monobactams”. It can kill certain types of bacteria (so-called Gram-negative bacteria).

Mar 22, 2024 · If approved, EMBLAVEO® will be indicated for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP), complicated urinary tract infections (cUTI), including pyelonephritis, and infections due to aerobic Gram-negative organisms with ...

4 days ago · The FDA has approved Abbvie’s aztreonam and avibactam monobactam/β-lactamase inhibitor combination antibiotic therapy, the first of its kind, under the name Emblaveo for treating complicated intra-abdominal infections (cIAI), including those caused by Gram-negative bacteria. 1. Emblaveo was approved in combination with metronidazole, for adult who …